NCT03000673View on ClinicalTrials.gov

A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 23, 2017

Primary Completion Date

October 23, 2017

Study Completion Date

October 23, 2017

Conditions
Antithrombotic
Interventions
DRUG

Enoxaparin

Specified dose of Enoxaparin on specified days

DRUG

unfractionated heparin (UFH)

Specified dose of UFH on specified days

DRUG

BMS-986177

Specified dose of BMS-986177 on specified day

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

55404

Davita Clinical Research, Minneapolis

80228

Davita Clinical Research, Lakewood

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY